Acadia Pharmaceuticals | ACAD - Equity Capital And Reserves


Acadia Pharmaceuticals reported $917.27M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
ALKERMES USD 1.82B 85.86M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Cara Therapeutics USD 27.87M 5.06M Sep/2025
Corcept Therapeutics USD 647.8M 15.9M Dec/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
Eisai JPY 889.64B 35.21B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
J&J USD 81.19B 358M Mar/2026
Moderna USD 8.65B 680M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Prothena USD 280.47M 14.51M Dec/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025